Sanofi's BTK inhibitor Wayrilz has become the first drug in the class to be approved by the FDA for immune thrombocytopenia (ITP), a rare autoimmune blood disorder. Wayrilz (rilzabrutinib) has been ...
If you have a Good Question you’d like us to try to answer, send it to [email protected]. If you have a Good Question you’d like us to try to answer, send it to [email protected]. If you have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback